JUPITER NEUROSCIENCES, INC. 8-K

What Happened
Jupiter Neurosciences, Inc. (JUNS) announced in an 8‑K that on May 19, 2026 it and PharmAla Biotech Holdings Inc. executed a non‑binding term sheet for a potential licensing transaction under which Jupiter would acquire exclusive, perpetual U.S. rights to ALA‑002 (a next‑generation MDMA formulation) and related IP, regulatory materials, inventory and certain contracts. The Company issued a press release on May 20, 2026 announcing the Term Sheet.

Key Details

• Upfront consideration at closing: $3,333,333 total — $1,500,000 cash + $1,833,333 in Jupiter equity (equity subject to a 180‑day lock‑up); Jupiter may elect all‑cash instead.
• Development and regulatory milestones: $3,333,333 upon initiation of a Phase 3 trial and $20,000,000 upon FDA approval.
• Commercial milestones and royalty: $10,000,000, $30,000,000 and $33,333,333 payable at first U.S. annual net sales of $333,333,333; $1,000,000,000; and $2,000,000,000, respectively; after all commercialization milestones are met PharmAla would receive a perpetual 3% royalty on U.S. net sales.
• Transaction mechanics and timing: Jupiter deposited $600,000 into escrow (credited to upfront cash); the parties expect to negotiate definitive agreements within 90 days and have a 90‑day exclusivity/no‑shop period; the Term Sheet is non‑binding except for specified provisions (escrow, confidentiality, exclusivity, fees/expenses).

Why It Matters
This Term Sheet, if converted into a definitive agreement, would add ALA‑002 to Jupiter’s U.S. development/commercial portfolio and create future contingent payment and royalty obligations tied to clinical progress, FDA approval, and sales milestones. The deal structure limits near‑term cash outlay but contemplates equity issuance (potential dilution) and milestone/royalty liabilities if the program advances. The arrangement is subject to due diligence, definitive agreements, shareholder and regulatory approvals, and there is no assurance the transaction will close.